CME: Thrombocytopenia & New Pathways Forward

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Thrombocytopenia & New Pathways Forward

Program Information
Thrombocytopenia & New Pathways Forward
Thrombocytopenia patients have always been blocked from receiving crucial therapeutic and diagnostic procedures—until now thanks to these advances.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Thrombocytopenia, or low platelet count, is the most frequent hematologic complication of chronic liver disease, and its impact can be devastating on patient care.  Due to the risk of bleeding, patients with thrombocytopenia are blocked from receiving crucial invasive therapeutic and diagnostic procedures, which affects those with severe disease the most. This leads to questions on how to best manage thrombocytopenic patients with chronic liver disease.

    This activity will discuss recent advances in therapeutic options for patients with severe thrombocytopenia caused by chronic liver disease.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Matt Birnholz, MD
    Medical Director
    Chicago, IL

    Dr. Birnholz has nothing to disclose. 

    Robert S. Brown, Jr., MD, MPH
    Gladys and Roland Harriman Professor of Medicine
    Vice Chair for Mentorship and Academic Development
    Department of Medicine
    Clinical Chief, Division of Gastroenterology and Hepatology
    Weill Cornell Medicine
    Center for Liver Disease
    New York, NY 

    Dr. Brown receives consulting fees from AbbVie, Dova Pharmaceuticals, Gilead, Intercept, Shionogi and has contracted research with AbbVie, Gilead, Intercept, Shionogi.

    Reviewers/Content Planners/Authors:

    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiological mechanisms and consequences of thrombocytopenia in patients with chronic liver disease.
    • Describe the mechanism of action, efficacy, and safety profiles of thrombopoietin receptor agonists for the treatment of thrombocytopenia in patients with chronic liver disease.
  • Target Audience

    This activity is designed to meet the educational needs of hepatologists and gastroenterologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Shionogi.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 9/18/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.